Research
Adherence
Adherence to dipeptidyl peptidase-4 (DPP4) inhibitor therapy has no significant association with weight change in patients with type 2 diabetes.
If you are prescribed a DPP4 inhibitor for type 2 diabetes, note that adherence does not significantly affect your weight. These medications are weight-neutral, so focus on other aspects of your treatment plan for weight management.
GoodRefutesHIGH confidence
Adherent and poorly adherent DPP4 patients experienced approximately the same amount of weight loss.
Why this rating
Large real-world observational study (n=2,272 DPP4) with regression adjustment.
Source
Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence
Ginger Smith Carls et al. · Obesity Science & Practice · 2017
cohort · n=5818Cited 27×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →